Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Apr 21, 2022 3:51pm
125 Views
Post# 34621619

RE:RE:trying to understand?

RE:RE:trying to understand?Pof's post is myopic. It's all negative. Bioasis is doing all of its work with partners. Partners have the resources to get things done. But they can only do so much before they'll have to pay Bioasis in a substantial deal.

Vaccinex was worthless. J&J would never announce a deal like this one with Bioasis. It's not material for such a large company. Prothena likely didn't have a payload worth advancing. I believe there's more to the Chiesi deal than 4 LSDs. MedImmune, who claimed that xB3 was the best transport they tested, was subsumed by AstraZeneca. AstraZeneca is in partnership with Daiichi Sankyo. It's unlikely that Daiichi Sankyo would partner with Bioasis on anything if there was a bad word from AstraZeneca. And Bioasis still has access to the Lind LOC. $7 million. That LOC was arranged to give Bioasis leverage in dealmaking. Since it was arranged, Bioasis has developed even more leverage in dealmaking by adding to its list of partners.

As I see it, everything is moving in the right direction. Pof's post is nonsense. I really hope he argues the point.

jd
<< Previous
Bullboard Posts
Next >>